全球抗生物質市場

全球抗生物質市場 是由出版商Global Industry Analysts, Inc.在2010年10月所出版的。 這份英文市場調查報告書包含Pages: 850 價格從美金4500起跳。

簡介

本報告書為全球抗生物質市場的相關分析，包含抗生物質概要與種類、FDA認可動向，同時包含產品技術革新動向、各國市場動向、企業簡介等，概述如下。

第1章 導論、方法論、產品定義

第2章 業界概要

• 抗生物質的耐性與副廠藥的競争對長期成長之影響
• 藥劑的使用促進了相關的新法規成長
• 現在以及將來分析

第3章 市場動向

第4章 競爭

• 競争激烈的市場

第5章 產品概要

• 抗生物質：導論
• 抗生物質耐性
• 抗生物質分類
• 抗生物質開發的主要里程碑
• 抗生物質種類

第6章 研究結果

第7章 FDA的認可與專利

第8章 近年業界活動

第9章 近年戰略的企業開發

第10章 產品革新與導入

第11章 近年的產品技術革新

第12章 相關企業

第13章 世界市場前景

第14章 美國

第15章 加拿大

第16章 日本

第17章 歐洲

• 法國
• 德國
• 義大利
• 英國
• 西班牙

第18章 亞太地區

第19章 其他地區

競爭檔案：197家（包含事業部門／子公司：238間）

目錄

Abstract

This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook"! Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

1. INTRODUCTION, METHODOLOGY &PRODUCT DEFINITIONS 1

• Study Reliability and Reporting Limitations1
• Disclaimers2
• Data Interpretation & Reporting Level2
• Quantitative Techniques & Analytics3
• Product Definitions and Scope of Study3
• Penicillin4
• Cephalosporins4
• Macrolides4
• Quinolones4
• Carbapenems4
• Other Antibiotics5
• Aminoglycosides5
• Tetracyclines5
• Sulfonamides5
• Mupirocin5
• Glycopeptides5
• Synercid6
• Oxazolidinones6
• Linezolid6

2. INDUSTRY OVERVIEW 7

• Antibiotic Resistance and Generic Competition to ImpactLong Term Growth7
• New Regulations Guiding Usage of Drugs to DriveGrowth7
• Current & Future Analysis7

3. MARKET DYNAMICS 9

• Anti-Bacterials Segment Drives Global Anti-Infectives Market9
• Antibiotic Resistance - A Primary Growth Inhibitor9
• Antibiotic-Resistant Bacteria by Type9
• Patent Expiries Commoditize Antibiotics10
• Patent Expiries of Leading Drugs in the Recent Past,Current, and Future (2000 -2013)10
• Anti-MRSA Antibiotics Find Their Way10
• Table 1: World MRSA Treatments (2007 & 2008) :Percentage Share Breakdown by Leading AntibioticDrugs -Vancomycin, Zyvox, Cubicin and Tygacil(includes corresponding Graph/Chart)11
• Key Antibiotics in Pipeline11

4. COMPETITION 12

• Highly Competitive Market12
• Table 2: Leading Players in the Worldwide AntibioticsMarket (2008): Percentage Breakdown by Value Salesfor Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson &Johnson, Bayer, Abbott, Wyeth, and Others(includes corresponding Graph/Chart)12
• GlaxoSmithKline - The Undisputed Leader ofPenicillin Market13
• Table 3: Worldwide Leading Antibiotics within PenicillinClass (2005 & 2006): Percentage Breakdown by Valuefor Augmentin, Zosyn/Tazocin, Amoxil, and Others(includes corresponding Graph/Chart)13
• GlaxoSmithKline Leads Cephalosporin Market14
• Table 4: Worldwide Leading Antibiotics withinCephalosporin Class (2005 & 2006): PercentageBreakdown by Value for Rocephin, Ceftin/Zinnat,Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin,and Others (includes corresponding Graph/Chart)14
• Pfizer Dominates Macrolides Market15
• Table 5: Worldwide Leading Antibiotics withinMacrolide Class (2005 & 2006): Percentage Breakdownby Value for Zithromax, Klaricid/Biaxin, Ketek,and Others (includes corresponding Graph/Chart)15
• Levaquin/Tavanic - The Most PreferredQuinolone Antibiotic16
• Table 6: Worldwide Leading Antibiotics withinQuinolone Class (2005 & 2006): PercentageBreakdown by Value for Levaquin/Tavanic, Avelox,Ciprobay/Ciproxin, Cravid, and Others (includescorresponding Graph/Chart)16
• Merck Rules Carbapenems Market17
• Table 7: Worldwide Leading Antibiotics withinCarbapenem Class (2005 & 2006): PercentageBreakdown by Value for Primaxin, Merrem,Invanz, and Others (includes correspondingGraph/Chart)17

5. PRODUCT OVERVIEW 18

• Antibiotics - An Introduction18
• Antibiotic Resistance18
• b-Lactams19
• Classification of Antibiotics20
• Key Milestones in Antibiotic Development20
• Antibiotic Types20
• Penicillin20
• History21
• About the Drug21
• Cephalosporins21
• Treatment22
• Effects of the Drug22
• Macrolides22
• Treatment23
• Quinolones23
• Table 8: Leading Global Ciprofloxacin Brands:(2006-2008) (includes correspondingGraph/Chart)23
• Carbapenems24
• Other Antibiotics24
• Aminoglycosides24
• Treatment24
• Effects of the Drug24
• Tetracyclines25
• Treatment25
• Effects of the Drug26
• Sulfonamides26
• Treatment26
• Effects of the Drug27
• Mupirocin27
• Glycopeptides27
• Synercid27
• Oxazolidinones28
• Linezolid28

6. RESEARCH FINDINGS 29

• New Design for Monitoring Toxin Delivery Activityof Pathogenic Bacteria29
• Cephalosporins Effective when Compared to Penicillin29
• FDA Bans Baytril Antibiotic for Chickens29
• Erythromycin Along with Some Specific Drugs IncreaseRisk of Sudden Death29
• Rise in Usage of Quinolones for Urinary Tract InfectionsLeads to Drug Resistance30
• Polyphor Discovers POL7080 - New Antibiotic AgainstGram-Negative Bacteria30

7. FDA APPROVALS/PATENTS 31

• MiddleBrook Obtains NDA Approval for MOXATAG(tm)31
• J&JPRD Seeks FDA Approval for DoripenemAntibiotic31
• J&JPRD Seeks FDA Approval for InvestigationalAntibiotic, Ceftobiprole31
• GSK Receives Approval for ALTARGO(r) in Europe31
• APL Receives FDA Approval for Cefpodoxime Proxetil32
• Cubist Receives Approval to Market CUBICINin Canada32
• Cubist Obtains Approval to Market CUBICIN forAdded Indications in EU32
• Cubist Gains Approval for CUBICIN in Taiwan andSouth Korea32
• Cethromycin Achieves FDA' s Orphan DrugDesignation32
• FDA Approves Wockhardt' s Cefotaxime Injection33
• FDA Approves Doxycycline Tablets33
• FDA Approves Clarithromycin33
• FDA Approves Doxycycline Tablets For The US Market33
• Johnson & Johnson Applies DoripenemFor FDA Approval33
• FDA Certifies Antibioticos do Brasil' s Plant33
• FDA Certifies ANDA For Cefdinir Capsules34
• US FDA Approves Teva' s Cefprozil Tablets34
• FDA Certifies ANDA for Cephalexin Capsules34
• American Pharmaceutical Partners Receives FDAApprovals for Ceftriaxone for Injection, USP34
• Advancis' s Keflex Receives FDA Approval34
• Wockhardt Gains Marketing Approval for Cefuroximeaxetil in the US34
• Wyeth' s Mylotarq Receives Government' s Approval35
• FDA Approves Generic Version of Zithromax35
• Pfizer Wins FDA Approval for Zmax(tm)35
• Venus Remedies Files Second PCT for NewCephalosporins36
• Falcon Gains US FDA Approval for its GenericAnti-Infective Solution36
• Cadilla Receives FDA Approval to MarketClindamycin36

8. RECENT INDUSTRY ACTIVITY 37

• DSM Opens Eco-friendly Antibiotics Plant ZOR-f,in the Netherlands37
• Daiichi Leverages Ranbaxy' s Network to Market Tavanicin South Africa and Romania37
• Pfizer Acquires Wyeth37
• Durata Therapeutics Acquires Pfizer' s VicuronPharmaceuticals37
• Cubist Completes Acquisition of Calixa Therapeutics38
• AstraZeneca to Acquire Novexel38
• Tianyin and Sichuan Mingxin to Establish an AntibioticJoint Venture38
• Pfizer and Aurobindo Pharma Ink Agreement for ProducingOff Patent Drugs39
• BMP Sunstone to Acquire Majority Stake in ZhangjiakouShengda39
• Novartis to Take Over Protez Pharmaceuticals39
• 3i to Buy Alpharma Unit40
• NCPC to Acquire Stake in DSM' s Antibiotics Division40
• ULL Establishes New Antibiotics Unit in HimachalPradesh40
• Biocat to Expand Presence in the Indian Market40
• PRWT Acquires Cherokee Chemical Unit from Merck40
• CSPC Joins Hands with Indonesian Firms41

9. STRATEGIC CORPORATE DEVELOPMENTS INTHE RECENT PAST - A PERSPECTIVE BUILDER 42

• Nisshin-Kyorin to Merge with Kyorin Pharmaceutical42
• Schering-Plough Acquires Organon BioSciences42
• GSK & Anacor Partner for Boron Chemistry-BasedAntibiotics and Antivirals42
• Iroko Bags Canadian Rights to Vancocin(r)43
• Cubist Licenses CUBICIN Rights to Merck43
• Sagent Partners with Astral to Develop InjectableAntibiotics43
• MR Healthcare to Manufacture New Antibiotics &Medicines43
• Livzon Synthetic to Acquire Antibiotic Intermediatefrom Jiaozuo44
• C&O Pharmaceutical to Distribute Meiact in China44
• Bioton Signs Deal to Market Antibiotics in Russia44
• Toyama Gains Marketing Approval for Geninax(r)in Japan44
• Forest Laboratories Acquires Cerexa44
• Oscient Modifies Licensing Agreement WithLG Life Sciences44
• Orchid Sign Licensing & Distribution Pact With Actavis45
• Forest Laboratories Revokes Partnership With Replidyne45
• SRI and Blanca Collaborate To Develop &Test Carbacephem45
• AstraZeneca To Expand Research Center For Antibiotics45
• Jade Pharmaceutical Begins Levofloxacin' sProduction in China45
• Reyoung To Start Antibiotic Production At New Facility46
• Toyama Begins T-705 Clinical Trials46
• SmPC For Sanofi-Aventis' Ketek(r) Updated46
• Lupin Receives Approval for CefpodoximeProxetil Antiobiotic Tablets in France46
• Antibiotice Plans To Infuse Funds For AntibioticsProduction46
• UAE Approves Pfizer' s Zithromax SD46

10. PRODUCT INNOVATIONS/INTRODUCTIONS 47

• Janssen-Cilag Launches Doribax(tm) - New CarbapenemAntibiotic47
• MIT Scientists Develop a New Antibiotic,
• Rhodostreptomycin47
• Watson Pharma Introduces Biaxin XL' s Generic Version47

11. PRODUCT INNOVATIONS IN THE RECENTPAST - A PERSPECTIVE BUILDER 48

• Toyama Launches New Garenoxacin Quinolone Antibiotic48
• Wockhardt to Introduce Cefprozil in the US48
• MSD India Launches Invanza in India48
• Orchid Chemicals to Introduce Three New Drugs in the US48
• DUSA Pharmaceuticals Releases ClindaReach(tm)49
• Mylan Releases Cipro' s Generic Version49
• Macrolide Antibiotic Developed In the US49
• University of Michigan Devises NMR SpectroscopyFor Antibiotics49
• Glycopeptide-Cephalosporin Antibiotics Developed In The US49
• Neosil Tests NEO 101 Antibiotic49
• New Antibiotic Developed By Canadian Inventors49
• Abbott Canada Releases FACTIVE(r) AntibioticTablets In Canada50
• Penicillin Binding Protein Found In Japan50
• Venus Remedies Releases Mucomelt-Forte50

12. FOCUS ON SELECT GLOBAL PLAYERS 51

• Abbott Laboratories (USA)51
• Astellas Pharma, Inc. (Japan)51
• Bayer HealthCare AG (Germany)51
• Bristol-Myers Squibb Co. (USA)52
• Cubist Pharmaceuticals, Inc. (USA)52
• Daiichi Sankyo Company, Limited (Japan)53
• Eli Lilly and Co. (USA)54
• GlaxoSmithKline Plc (UK)54
• Johnson & Johnson (USA)55
• Kyorin Pharmaceutical Co., Ltd. (Japan)55
• LG Life Sciences Limited (Korea)56
• MiddleBrook(tm) Pharmaceuticals, Inc. (USA)57
• Novartis AG (Switzerland)57
• Pfizer Inc. (USA)58
• Pliva d.d. (Croatia)59
• Roche (Switzerland)59
• Sanofi-Aventis SA (France)59
• Takeda Pharmaceutical Company, Ltd. (Japan)60
• Toyama Chemical Co., Ltd. (Japan)60

13. GLOBAL MARKET PERSPECTIVE 61

• Table 9: World Recent Past, Current & Future Analysisfor Antibiotics by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)61
• Table 10: World Historic Review for Antibiotics byGeographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)62
• Table 11: World 11-Year Perspective for Antibioticsby Geographic Region - Percentage Breakdown ofDollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)63
• Table 12: World Recent Past, Current & Future Analysisfor Penicillin by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007through 2015 (includes correspondingGraph/Chart)64
• Table 13: World Historic Review for Penicillin byGeographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)65
• Table 14: World 11-Year Perspective for Penicillin by Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)66
• Table 15: World Recent Past, Current & Future Analysisfor Cephalosporin by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)67
• Table 16: World Historic Review for Cephalosporin by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)68
• Table 17: World 11-Year Perspective for Cephalosporinby Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)69
• Table 18: World Recent Past, Current & Future Analysisfor Macrolides by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)70
• Table 19: World Historic Review for Macrolides byGeographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)71
• Table 20: World 11-Year Perspective for Macrolidesby Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)72
• Table 21: World Recent Past, Current & Future Analysisfor Quinolones by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)73
• Table 22: World Historic Review for Quinolones byGeographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)74
• Table 23: World 11-Year Perspective for Quinolones by Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)75
• Table 24: World Recent Past, Current & Future Analysisfor Carbapenems by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)76
• Table 25: World Historic Review for Carbapenems byGeographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)77
• Table 26: World 11-Year Perspective for Carbapenemsby Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of WorldMarkets for Years 2005, 2010 & 2015 (includescorresponding Graph/Chart)78
• Table 27: World Recent Past, Current & FutureAnalysis for Other Antibiotics by Geographic Region -US, Canada, Japan, Europe, Asia-Pacific (excludingJapan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Millionfor Years 2007 through 2015 (includescorresponding Graph/Chart)79
• Table 28: World Historic Review for Other Antibiotics by Geographic Region - US, Canada, Jap an, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2006 (includescorresponding Graph/Chart)80
• Table 29: World 11-Year Perspective for Other Antibioticsby Geographic Region - Percentage Breakdown of DollarSales for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets forYears 2005, 2010 & 2015 (includescorresponding Graph/Chart)81

14. THE UNITED STATES 82

A. Market Analysis 82

• Current and Future Analysis82
• Antibiotics Approved Between 2000 and 2005in the United States82
• Competition83
• Table 30: Leading Players in the US AntibioticsMarket (2008): Percentage Breakdown byValue Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others(includes corresponding Graph/Chart)83
• Key Players83

B. Market Analytics 84

• Table 31: US Recent Past, Current & Future Analysisfor Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)84
• Table 32: US Historic Review for Antibiotics byProduct Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics MarketsIndependently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes corresponding Graph/Chart)85
• Table 33: US 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown ofDollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems andOther Antibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)86

15. CANADA 87

A. Market Analysis 87

• Current And Future Analysis87

B. Market Analytics 87

• Table 34: Canadian Recent Past, Current &Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales inUS$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)87
• Table 35: Canadian Historic Review for Antibioticsby Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenemsand Other Antibiotics Markets IndependentlyAnalyzed with Annual Sales in US$ Millionfor Years 2000 through 2006 (includescorresponding Graph/Chart)88
• Table 36: Canadian 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown ofDollar Sales for Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)89

16. JAPAN 90

A. Market Analysis 90

• Current and Future Analysis90
• Key Players90

B. Market Analytics 91

• Table 37: Japanese Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)91
• Table 38: Japanese Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000 through2006 (includes corresponding Graph/Chart)92
• Table 39: Japanese 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown ofDollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems andOther Antibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)93

17. EUROPE 94

A. Market Analysis 94

• Current and Future Analysis94

B. Market Analytics 95

• Table 40: European Recent Past, Current & FutureAnalysis for Antibiotics by Geographic Region -France, Germany, Italy, UK, Spain, andRest of Europe Markets Independently Analyzedwith Annual Sales in US$ Million for Years 2007through 2015 (includes correspondingGraph/Chart)95
• Table 41: European Historic Review for Antibioticsby Geographic Region - France, Germany, Italy,UK, Spain, and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales in US$ Millionfor Years 2000 through 2006 (includescorresponding Graph/Chart)96
• Table 42: European Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)97
• Table 43: European Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and OtherAntibiotics Markets Independently Analyzedwith Annual Sales in US$ Million for Years 2000through 2006 (includes corresponding Graph/Chart)98
• Table 44: European 11-Year Perspective for Antibioticsby Geographic Region - Percentage Breakdown ofDollar Sales for France, Germany, Italy, UK, Spain,and Rest of Europe Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)99
• Table 45: European 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdownof Dollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems, andOther Antibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)100

17a. FRANCE 101

• A. Market Analysis101
• Current and Future Analysis101
• Trends101
• Over Consumption of Antibiotics - Cause of Concern101
• Sanofi-Aventis SA - A Key Player101
• B. Market Analytics102
• Table 46: French Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales inUS$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)102
• Table 47: French Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes corresponding Graph/Chart)103
• Table 48: French 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown ofDollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems andOther Antibiotics Markets for2005, 2010 & 2015(includes corresponding Graph/Chart)104

17b. GERMANY 105

A. Market Analysis 105

• Current and Future Analysis105
• Bayer HealthCare AG - A Key Player105

B. Market Analytics 106

• Table 49: German Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$Million for Years 2007 through 2015(includes corresponding Graph/Chart)106
• Table 50: German Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000 through2006 (includes corresponding Graph/Chart)107
• Table 51: German 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdownof Dollar Sales for Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)108

17c. ITALY 109

A. Market Analysis 109

• Current and Future Analysis109

B. Market Analytics 109

• Table 52: Italian Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)109
• Table 53: Italian Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes corresponding Graph/Chart)110
• Table 54: Italian 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdownof Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems andOther Antibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)111

17d. THE UNITED KINGDOM 112

A. Market Analysis 112

• Current And Future Analysis112
• GlaxoSmithKline Plc - A Key Player112

B. Market Analytics 113

• Table 55: UK Recent Past, Current & Future Analysisfor Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenemsand Other Antibiotics Markets Independently Analyzedwith Annual Sales in US$ Million for Years 2007through 2015 (includes correspondingGraph/Chart)113
• Table 56: UK Historic Review for Antibiotics byProduct Segment - Penicillin, Cephalosporin,acrolides, Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes correspondingGraph/Chart)114
• Table 57: UK 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdownof Dollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems andOther Antibiotics Markets for2005,2010 & 2015 (includes correspondingGraph/Chart)115

17e. SPAIN 116

• Market Analysis116
• Table 58: Spanish Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment -Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)116
• Table 59: Spanish Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes correspondingGraph/Chart)117
• Table 60: Spanish 11-Year Perspective for Antibioticsby Product Segment - Percentage Breakdownof Dollar Sales for Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems andOther Antibiotics Markets for 2005, 2010 & 2015(includes corresponding Graph/Chart)118

17f. REST OF EUROPE 119

A. Market Analysis 119

• Current and Future Analysis119
• Poland119
• Table 61: Polish Market for Antibiotics (2008):Percentage Breakdown of Market Share by Leading Companies - GSK Pharma, Bioton, Sandoz Corp,Ranbaxy and Others (includes correspondingGraph/Chart)119
• Focus On Select Players119

B. Market Analytics 120

• Table 62: Rest of Europe Recent Past, Current &Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)120
• Table 63: Rest of Europe Historic Review for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)121
• Table 64: Rest of Europe 11-Year Perspective forAntibiotics by Product Segment - PercentageBreakdown of Dollar Sales for Penicillin,Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Marketsfor 2005, 2010 & 2015 (includescorresponding Graph/Chart)122

18. ASIA-PACIFIC 123

A. Market Analysis 123

• Current and Future Analysis123
• India123
• Rising Prices of Penicillin G to Affect AntibioticsProduction123
• Market for Injectable Antibiotics Poised to Grow123
• Cipla, Pharmaceutical Market Leader in 2009124
• China124
• Carbapenem Witnesses Robust Growth in China124
• Key Players125
• Ranbaxy Laboratories Ltd. (India)125

B. Market Analytics 126

• Table 65: Asia-Pacific Recent Past, Current &Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)126
• Table 66: Asia-Pacific Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000through 2006 (includes corresponding Graph/Chart)127
• Table 67: Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)128

19. REST OF WORLD 129

A. Market Analysis 129

• Current and Future Analysis129

B. Market Analytics 130

• Table 68: Rest of World Recent Past, Current &Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Salesin US$ Million for Years 2007 through2015 (includes corresponding Graph/Chart)130
• Table 69: Rest of World Historic Review for Antibioticsby Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed withAnnual Sales in US$ Million for Years 2000 through 2006(includes corresponding Graph/Chart)131
• Table 70: Rest of World 11-Year Perspective forAntibiotics by Product Segment - PercentageBreakdown of Dollar Sales for Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenemsand Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)132

COMPETITION

相關商品